NCT00454909View on ClinicalTrials.gov

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.

PHASE2CompletedINTERVENTIONAL
Enrollment

873

Participants

Timeline

Start Date

April 23, 2007

Primary Completion Date

October 31, 2007

Study Completion Date

April 11, 2008

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

Meningococcal vaccine 134612

Single dose intramuscular injection.

BIOLOGICAL

Menactra®

Single dose intramuscular injection.

Trial Locations (10)

94015

GSK Investigational Site, Daly City

94063

GSK Investigational Site, Redwood City

94533

GSK Investigational Site, Fairfield

94589

GSK Investigational Site, Vallejo

94596

GSK Investigational Site, Walnut Creek

95815

GSK Investigational Site, Sacramento

96792

GSK Investigational Site, Waianae

96797

GSK Investigational Site, Waipio

96814

GSK Investigational Site, Honolulu

96819

GSK Investigational Site, Honolulu

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY